Could soluble CD24 offer some hope against severe COVID-19?
A recent randomized phase III trial conducted by researchers at the Ohio State University, Columbus, OH, US, evaluated the impact of CD24Fc in severe COVID-19 patients and showed promising clinical efficacy. This study is available as a preprint on the medRxiv* server.
Susha Cheriyedath Ohio State University Immunological Insights Into Therapeutic Roles Against Severe Image Credit
Source: news-medical.net